An open-label clinical pilot treated three progressive glaucoma patients with murine NGF eye drops (200 μg/mL, four times daily for seven weeks) and observed improvements in visual acuity, contrast sensitivity, visual field, and electrophysiological measures—with no reported intraocular pressure worsening [227]. This evidence concerns the gene NGF and glaucoma.